Key result
Sotatercept advances PAH treatment as a landmark therapy targeting activin pathways for reverse remodeling.
Why the study?
Despite improved outcomes with treatments targeting three main pathways, there remains a critical need for novel therapies addressing different mechanisms of pulmonary arterial hypertension.
Does sotatercept improve outcomes in adult PAH patients with WHO functional class II or III symptoms on background therapy?
Does sotatercept improve outcomes in adult PAH patients with WHO functional class II or III symptoms on background therapy?
Sotatercept represents a landmark advancement in PAH treatment by targeting reverse remodeling in the pulmonary vasculature and right ventricle.
No takes yet. Share an insight, caveat, or question.
Highlights potential for disease-modifying PAH therapy; leaves open confirmation of clinical benefit in randomized settings.
Anand et al. (2025) conducted a review in Pulmonary arterial hypertension (PAH). Sotatercept was evaluated. Sotatercept, a novel fusion protein targeting activin and growth differentiation factors, represents a landmark advancement in pulmonary arterial hypertension treatment aimed at reverse remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: